
Nexstim H2 2022 - Slight miss – but profitability in sight

Redeye provides a research update after Nexstim's H2 report, which came in slightly below our projections. As a result, we have made minor adjustments to our base case and provided our perspective on 2023.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Nexstim H2 2022 - Slight miss – but profitability in sight](#)